ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

PATIENT REPORT

Patient Age/Sex: Unknown

Specimen Collected: 18-Dec-23 09:34

Autoimmune Dysautonomia Panel, Serum | **Received: 18-Dec-23 09:40** | **Report/Verified: 18-Dec-23 09:53**

Procedure	Result	Units	Reference Interval
Purkinje Cell/Neuronal Nuclear IgG Scrn	**PCCA Detected** * f1 i1		[None Detected]
CASPR2 Ab IgG CBA-IFA Screen, Serum	**Detected** * t1 i2		[<1:10]
LGI1 Ab IgG CBA-IFA Screen,Serum	**Detected** * t2 i3		[<1:10]
CV2 Ab IgG CBA-IFA Screen,Serum	**Detected** * t3 i4		[<1:100]
DPPX Ab IgG CBA-IFA Screen,Serum	**Detected** * t4 i5		[<1:10]
Ganglionic Acetylcholine Receptor Ab	**10.0** H i6	pmol/L	[0.0-8.4]

Neuronal Nuclear Ab IgG, Immunoblot, Hu | **Received: 18-Dec-23 09:40** | **Report/Verified: 18-Dec-23 09:53**

Procedure	Result	Units	Reference Interval
Neuronal Nuclear Ab (Hu) IgG,IB, Serum	**Positive** * i7		[Negative]

Purkinje Cell Ab Titer, IgG | **Received: 18-Dec-23 09:40** | **Report/Verified: 18-Dec-23 09:53**

Procedure	Result	Units	Reference Interval
Purkinje Cell Antibody Titer IgG	**1:40** * i8		[<1:10]

CASPR2 Ab IgG Titer by CBA-IFA, Ser | **Received: 18-Dec-23 09:40** | **Report/Verified: 18-Dec-23 09:53**

Procedure	Result	Units	Reference Interval
CASPR2 Ab IgG CBA-IFA Titer, Serum	**1:80** * i9		[<1:10]

CV2 Ab IgG Titer by CBA-IFA, Ser | **Received: 18-Dec-23 09:40** | **Report/Verified: 18-Dec-23 09:53**

Procedure	Result	Units	Reference Interval
CV2 Ab IgG CBA-IFA Titer,Serum	**1:1600** * i10		[<1:100]

DPPX Ab IgG Titer by CBA-IFA, Ser | **Received: 18-Dec-23 09:40** | **Report/Verified: 18-Dec-23 09:53**

Procedure	Result	Units	Reference Interval
DPPX Ab IgG CBA-IFA Titer,Serum	**1:160** * i11		[<1:10]

LGI1 Ab IgG Titer by CBA-IFA, Ser | **Received: 18-Dec-23 09:40** | **Report/Verified: 18-Dec-23 09:53**

Procedure	Result	Units	Reference Interval
LGI1 Ab IgG CBA-IFA Titer,Serum	**1:80** * i12		[<1:10]

Interpretive Text

t1: 18-Dec-23 09:34 (CASPR2 Ab IgG CBA-IFA Screen, Serum)
CASPR2 Antibody, IgG is detected. Titer results to follow.

t2: 18-Dec-23 09:34 (LGI1 Ab IgG CBA-IFA Screen, Serum)
LGI1 Antibody, IgG is detected. Titer results to follow.

t3: 18-Dec-23 09:34 (CV2 Ab IgG CBA-IFA Screen, Serum)
CV2 Antibody, IgG is detected. Titer results to follow. Additional charges apply.

t4: 18-Dec-23 09:34 (DPPX Ab IgG CBA-IFA Screen, Serum)
DPPX Antibody, IgG is detected. Titer results to follow.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Result Footnote

f1: Purkinje Cell/Neuronal Nuclear IgG Scrn

Antibodies detected, therefore IFA titer and Immunoblot testing to be performed.

Test Information

i1: Purkinje Cell/Neuronal Nuclear IgG Scrn

INTERPRETIVE INFORMATION: Purkinje Cell/Neuronal Nuclear IgG Scrn

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i2: CASPR2 Ab IgG CBA-IFA Screen, Serum

INTERPRETIVE INFORMATION: CASPR2 Ab IgG CBA-IFA Screen, Serum

Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, including acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. Tumors such as thymoma, small cell lung cancer, and other rarer tumors may occur. The full-spectrum of clinical disorders and tumors associated with the CASPR2 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CASPR2 transfected cell lines for the detection and semiquantification of the CASPR2 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i3: LGI1 Ab IgG CBA-IFA Screen, Serum

INTERPRETIVE INFORMATION: LGI1 Ab IgG CBA-IFA Screen, Serum

Leucine-rich, glioma-inactivated 1 protein (LGI1) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of LGI1 IgG antibody is mainly associated with limbic encephalitis, hyponatremia, and myoclonic movements. LGI1 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia, and idiopathic epilepsy. The full-spectrum of clinical disorders associated with the LGI1 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

Test Information

i3: LGI1 Ab IgG CBA-IFA Screen, Serum

This indirect fluorescent antibody assay utilizes LGI1 transfected cell lines for the detection and semiquantification of the LGI1 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i4: CV2 Ab IgG CBA-IFA Screen, Serum

INTERPRETIVE INFORMATION: CV2 Ab IgG CBA-IFA Screen, Serum

CV2 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2 is associated with small-cell lung cancer and thymoma. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CV2 transfected cell lines for the detection and semiquantification of the CV2 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i5: DPPX Ab IgG CBA-IFA Screen, Serum

INTERPRETIVE INFORMATION: DPPX Ab IgG CBA-IFA Screen, Serum

DPPX antibody is found in a subset of patients with autoimmune encephalitis, and is often associated with prodromal gastrointestinal symptoms and unintentional weight loss. It may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes DPPX transfected cells for the detection and semiquantification of the DPPX IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

i6: Ganglionic Acetylcholine Receptor Ab

REFERENCE INTERVAL: Ganglionic Acetylcholine Receptor Ab

Negative . . . . . 0.0-8.4 pmol/L

Test Information

i6: Ganglionic Acetylcholine Receptor Ab
Indeterminate. . . . . 8.5-11.6 pmol/L
Positive . . . . . 11.7 pmol/L or greater

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i7: Neuronal Nuclear Ab (Hu) IgG, IB, Serum
INTERPRETIVE INFORMATION: Neuronal Nuclear Ab IgG, Immunoblot, Hu
This test detects IgG antineuronal antibodies to Hu antigens.

Antineuronal antibodies serve as markers that aid in discriminating between a true paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-Hu (antineuronal nuclear antibody, type I) is associated with small-cell lung cancer.

The presence of these antineuronal antibodies supports a clinical diagnosis of PND and should lead to a focused search for the underlying neoplasm.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

i8: Purkinje Cell Antibody Titer IgG
INTERPRETIVE INFORMATION: Purkinje Cell Ab Titer, IgG

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i9: CASPR2 Ab IgG CBA-IFA Titer, Serum
INTERPRETIVE INFORMATION: CASPR2 Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i10: CV2 Ab IgG CBA-IFA Titer, Serum
INTERPRETIVE INFORMATION: CV2 Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug

Test Information

i10: CV2 Ab IgG CBA-IFA Titer, Serum
Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i11: DPPX Ab IgG CBA-IFA Titer, Serum
INTERPRETIVE INFORMATION: DPPX Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i12: LGI1 Ab IgG CBA-IFA Titer, Serum
INTERPRETIVE INFORMATION: LGI1 Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.